Hope and advances in research
Testimonial
These authentic narratives showcase the experiences of individuals who have benefited from the latest medical advancements and innovative treatments. Their testimonials provide an inspiring glimpse into the progress made in the fight against the disease, as well as encouraging perspectives for the future.
Testimonial of Robert and his son, Jean-Marc Evenat
Testimonial of Ovila Blanchard
Testimonial of Roger et Claire Kelly
Other pages that might interest you
Additional Information - Testimonials
Advanced prostate cancer treatments strategies
Strategies for treating advanced cancer have significantly evolved, offering new options and hope for patients.
The role of hormone therapy
Has your doctor recommended hormone therapy? This video is for you!
States of prostate cancer following treatment
Do your recent tests show an increase in PSA levels? It could indicate a recurrence.
Targeted therapy and inherited mutations
If you have a specific genetic mutation, you could benefit from new targeted treatments.
Q-A – New therapies for advance prostate cancer
In this interview, we answer patients’ questions about new therapies for advanced prostate cancer.
All about hormone therapy
Hormone therapy can reduce tumor size, control cancer, and prolong life. Is it the right treatment for your cancer?
How to treat advanced prostate cancer
Advanced prostate cancer encompasses various conditions, including metastatic, recurrent, and hormone-resistant forms, each raising different questions and concerns.
ZYTIGA® – Now Reimbursed in Quebec
ZYTIGA®* Now Reimbursed in Québec for Use Prior to Chemotherapy In Men with Metastatic Prostate Cancer. Men with metastatic castration-resistant prostate cancer (mCRPC) in Québec now have access to a therapy that can be used prior to chemotherapy. Effective February 3, 2014, the province has added ZYTIGA® (abiraterone acetate) to the public drug formulary for the […]
Two-drug combination may improve survival in men with advanced cancer
Treating men with advanced prostate cancer using a two-drug combination may significantly increase survival. Indeed, a Harvard-affiliated medical research team found that patients with advanced prostate cancer treated with a combination of ADT and a chemotherapy drug called docetaxel lived approximately 14-17 months longer than men who started their treatment on ADT alone. These results […]
Health Canada Approves New Indication for Castration-Resistant Prostate Cancer
New Indication for the Use of Xtandi® (enzalutamide) Capsules Approval based on improved overall survival, delayed time to radiographic progression and an overall positive risk-benefit profile In the Phase III PREVAIL trial, men receiving enzalutamide therapy exhibited a statistically significant improvement in both overall survival and delayed time to radiographic progression or death as compared to […]
Sources and references
Last medical and editorial review: April 2024. See our web page validation committee and our collaborators by clicking here.
